Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Gossamer Bio, Inc. Common Stock

GOSS

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

Last trade $10.49
Day change -$0.49 (-4.46%)
Day range $10.27 – $11.37
Volume 126,232
Market cap $67M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$67.16M
Price / earnings
—
Price / book
-0.55×
Price / sales
0.86×
EV / sales
0.68×
EV / EBITDA
-0.46×

Profitability

Earnings per share
-$20.45
Return on assets
-194.4%
Return on equity
101.86%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.3×
Current ratio
0.6×
Quick ratio
0.6×
Cash ratio
0.51×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$156.04M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GOSS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$38.43M$9.24M$16.96M$13.8M$13.29M$11.49M$9.89M$9.38M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$38.43M$9.24M$16.96M$13.8M$13.29M$11.49M$9.89M$9.38M
Selling, general and administrative$9.64M$8.9M$18.75M$10.9M$9.39M$8.68M$8.66M$9.4M
Research and development$21.6M$26.41M$43.08M$48.93M$53.02M$41.58M$38.04M$36.11M
Total operating expenses$31.24M$35.31M$61.82M$59.84M$62.41M$50.25M$46.7M$45.51M
Operating income$7.2M-$26.07M-$44.87M-$46.04M-$49.11M-$38.77M-$36.81M-$36.13M
Interest expense-$2.46M-$2.71M-$2.76M-$2.75M-$2.75M-$2.74M-$2.75M-$2.74M
Income before taxes-$48.07M$16.9M-$46.66M-$47.33M-$48.22M-$38.27M-$36.64M-$35.44M
Income taxes$0$0$0-$88K$0$0$0-$2.41M
Net income-$48.07M$16.9M-$46.66M-$47.24M-$48.22M-$38.27M-$36.64M-$33.03M
Net income attributable to common shareholders-$48.07M$16.9M-$46.66M-$47.24M-$48.22M-$38.27M-$36.64M-$33.03M
EBITDA$7.2M-$26.07M-$44.86M-$52.33M-$49.11M-$38.76M-$36.8M-$45.76M
Basic earnings per share-$7.36$4.00-$16.00-$16.29-$16.92-$13.60-$12.80-$11.66
Diluted earnings per share-$7.36-$6.40-$16.00-$16.29-$16.92-$13.60-$12.80-$12.33

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Does Gossamer Bio (GOSS) Have the Potential to Rally 659.56% as Wall Street Analysts Expect?

Gossamer Bio (GOSS) has gained 30.3% over the past four weeks and trades at $10.98. Wall Street analysts have a mean price target of $83.4, suggesting potential upside of 659.6%. The stock holds a Zacks Rank #2 (Buy) rating, supported by strong earnings estimate revisions with consensus estimates up 35.9% over the past month. However, the article cautions that price targets should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.

Zacks Investment Research

TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates

TG Therapeutics (TGTX) reported Q3 2026 earnings of $0.35 per share, beating consensus estimates of $0.28, with revenues of $259.94 million exceeding expectations by 5.17%. The stock has gained 100.7% year-to-date and received a Zacks Rank #1 (Strong Buy) rating based on favorable estimate revisions. The company's Medical - Biomedical and Genetics industry ranks in the top 43% of Zacks industries.

GlobeNewswire Inc.

Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.

GlobeNewswire Inc.

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its Phase 3 PROSERA study design, specifically concealing adverse facts about placebo response controls at certain testing sites.

GlobeNewswire Inc.

GOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS

A securities class action lawsuit has been filed against Gossamer Bio (GOSS) alleging executives concealed placebo response risks in the Phase 3 PROSERA trial for seralutinib. The trial failed to meet its primary endpoint on February 23, 2026, causing an 80% stock price decline. The complaint claims management misled investors about trial design and patient recruitment despite knowing of significant placebo effects, particularly at Latin American sites.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 11, 20261-for-80reverse split